Airway microbiota in patients with synchronous multiple primary lung cancer: the bacterial topography of the respiratory tract. Airway microbiota in patients with synchronous multiple primary lung cancer: the bacterial topography of the respiratory tract

we analyzed the characteristics of the respiratory microbiome, which was collected from different sites and using different sampling methods. Overall design: We used the Antakli modifications as the basic criteria for the definition of sMPLC. The details are as follows: (1) one lesion in each patient must be diagnosed as an adenocarcinoma; (2) that the lesions are in anatomically distinct regions; (3) that there are no systemic metastases; (4) that there is no mediastinal spread as confirmed by postoperative pathology; and (5) possessing two or more of the following: (i) one tumor diagnosed as an adenomatous tumor, i.e., minimally invasive carcinoma, or invasive AD[3], and another tumor diagnosed as either squamous carcinoma or small cell lung cancer; (ii) different driver gene mutations; and (iii) different biomarker patterns[11]. The inclusion criteria were as follows: (1) patients diagnosed with sMPLC, as previously described, and all lesions located in the right upper lobe (RUL); (2) aged ≥18 years; (3) no contraindications for pulmonary surgery, i.e., distant metastasis, bleeding tendency, blood clotting disorders, cardiopulmonary insufficiency, severe arrhythmia or hypertension, pulmonary hypertension, and acute respiratory infection; (4) no other prior therapies; (5) expected survival >2 months; (6) without a history of other primary malignant tumors; (7) agreeing to participate in this study. Exclusion criteria included patients with poorly controlled diabetes, prior cerebrovascular events, active second malignancy, uncontrolled concommitant illness, or other conditions that might affect their participation in the study. We used the Antakli modifications as the basic criteria for the definition of sMPLC [10]. The details are as follows: (1) one lesion in each patient must be diagnosed as an adenocarcinoma; (2) that the lesions are in anatomically distinct regions; (3) that there are no systemic metastases; (4) that there is no mediastinal spread as confirmed by postoperative pathology; and (5) possessing two or more of the following: (i) one tumor diagnosed as an adenomatous tumor, i.e., minimally invasive carcinoma, or invasive AD[3], and another tumor diagnosed as either squamous carcinoma or small cell lung cancer; (ii) different driver gene mutations; and (iii) different biomarker patterns[11]. The inclusion criteria were as follows: (1) patients diagnosed with sMPLC, as previously described, and all lesions located in the right upper lobe (RUL); (2) aged ≥18 years; (3) no contraindications for pulmonary surgery, i.e., distant metastasis, bleeding tendency, blood clotting disorders, cardiopulmonary insufficiency, severe arrhythmia or hypertension, pulmonary hypertension, and acute respiratory infection; (4) no other prior therapies; (5) expected survival >2 months; (6) without a history of other primary malignant tumors; (7) agreeing to participate in this study. Exclusion criteria included patients with poorly controlled diabetes, prior cerebrovascular events, active second malignancy, uncontrolled concommitant illness, or other conditions that might affect their participation in the study.

本研究分析了经不同采样位点、采用不同采样方法获取的呼吸道微生物组（respiratory microbiome）特征。研究整体设计如下：本研究以安塔克利修正标准（Antakli modifications）作为同步多原发性肺癌（sMPLC）的定义基准，具体细则如下：（1）每位患者的病灶中必须有1处被诊断为腺癌；（2）病灶位于解剖学上相互独立的区域；（3）无全身远处转移；（4）经术后病理证实无纵隔播散；（5）满足以下任意2项及以上条件：（i）1处肿瘤被诊断为腺瘤性肿瘤，即微浸润癌或浸润性腺癌（AD）[3]，且另一处肿瘤被诊断为鳞状细胞癌或小细胞肺癌；（ii）存在不同的驱动基因突变；（iii）具有不同的生物标志物谱[11]。纳入标准如下：（1）经前述标准确诊为sMPLC，且所有病灶均位于右肺上叶（RUL）；（2）年龄≥18岁；（3）无肺手术禁忌证，即无远处转移、出血倾向、凝血功能障碍、心肺功能不全、严重心律失常或高血压、肺动脉高压以及急性呼吸道感染；（4）未接受过其他前期治疗；（5）预期生存期＞2个月；（6）无其他原发性恶性肿瘤病史；（7）同意参与本研究。排除标准包括血糖控制不佳的糖尿病患者、既往有脑血管事件病史者、活动性第二原发恶性肿瘤患者、未得到控制的合并症患者，以及其他可能影响本研究参与的其他情况。本研究再次以安塔克利修正标准（Antakli modifications）作为sMPLC的定义基准[10]，具体细则如下：（1）每位患者的病灶中必须有1处被诊断为腺癌；（2）病灶位于解剖学上相互独立的区域；（3）无全身远处转移；（4）经术后病理证实无纵隔播散；（5）满足以下任意2项及以上条件：（i）1处肿瘤被诊断为腺瘤性肿瘤，即微浸润癌或浸润性腺癌（AD）[3]，且另一处肿瘤被诊断为鳞状细胞癌或小细胞肺癌；（ii）存在不同的驱动基因突变；（iii）具有不同的生物标志物谱[11]。纳入标准如下：（1）经前述标准确诊为sMPLC，且所有病灶均位于右肺上叶（RUL）；（2）年龄≥18岁；（3）无肺手术禁忌证，即无远处转移、出血倾向、凝血功能障碍、心肺功能不全、严重心律失常或高血压、肺动脉高压以及急性呼吸道感染；（4）未接受过其他前期治疗；（5）预期生存期＞2个月；（6）无其他原发性恶性肿瘤病史；（7）同意参与本研究。排除标准包括血糖控制不佳的糖尿病患者、既往有脑血管事件病史者、活动性第二原发恶性肿瘤患者、未得到控制的合并症患者，以及其他可能影响本研究参与的其他情况。